With Trump's tariffs looming, is this really the appropriate time to load up on pharma stocks? And where does Cipla stand in ...

Monument Therapeutics, a precision-neuroscience company focused on the development of innovative treatments for serious central nervous system disorders (CNS), today announced two key leadership ...

Evotec’s cost-cutting drive has reached its pipeline. The company axed around 30% of its asset portfolio and offloaded ...

BMY and VERV are in the spotlight this week following the failure of a late-stage study and positive cholesterol study data, ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol-Myers Squibb (BMY – Research Report) and ...

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...

According to DelveInsight's analysis, the market for GIST is anticipated to increase during the forecast period (2025–2034), owing to the launch of e ...

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Numerous therapeutic classes, such as hematology, ...

According to analysts at BMO Capital Markets, non-obstructive hypertrophic cardiomyopathy would have meant a $1.3 billion ...

We recently published a list of the 10 Best Value Dividend Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands ...

US pharma major Bristol Myers Squibb (NYSE: BMY) yesterday disclosed that its Phase III ODYSSEY-HCM trial of Camzyos ...